1. Home
  2. VERV vs TBLD Comparison

VERV vs TBLD Comparison

Compare VERV & TBLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VERV
  • TBLD
  • Stock Information
  • Founded
  • VERV 2018
  • TBLD 2021
  • Country
  • VERV United States
  • TBLD United States
  • Employees
  • VERV N/A
  • TBLD N/A
  • Industry
  • VERV Medicinal Chemicals and Botanical Products
  • TBLD Investment Managers
  • Sector
  • VERV Health Care
  • TBLD Finance
  • Exchange
  • VERV Nasdaq
  • TBLD Nasdaq
  • Market Cap
  • VERV 601.2M
  • TBLD 535.4M
  • IPO Year
  • VERV 2021
  • TBLD N/A
  • Fundamental
  • Price
  • VERV $5.19
  • TBLD $17.61
  • Analyst Decision
  • VERV Strong Buy
  • TBLD
  • Analyst Count
  • VERV 5
  • TBLD 0
  • Target Price
  • VERV $25.20
  • TBLD N/A
  • AVG Volume (30 Days)
  • VERV 1.5M
  • TBLD 99.9K
  • Earning Date
  • VERV 11-05-2024
  • TBLD 01-01-0001
  • Dividend Yield
  • VERV N/A
  • TBLD 7.85%
  • EPS Growth
  • VERV N/A
  • TBLD N/A
  • EPS
  • VERV N/A
  • TBLD N/A
  • Revenue
  • VERV $20,648,000.00
  • TBLD N/A
  • Revenue This Year
  • VERV $57.08
  • TBLD N/A
  • Revenue Next Year
  • VERV N/A
  • TBLD N/A
  • P/E Ratio
  • VERV N/A
  • TBLD N/A
  • Revenue Growth
  • VERV 279.70
  • TBLD N/A
  • 52 Week Low
  • VERV $4.31
  • TBLD $13.44
  • 52 Week High
  • VERV $20.12
  • TBLD $16.26
  • Technical
  • Relative Strength Index (RSI)
  • VERV 42.56
  • TBLD 67.06
  • Support Level
  • VERV $5.28
  • TBLD $17.06
  • Resistance Level
  • VERV $5.96
  • TBLD $17.51
  • Average True Range (ATR)
  • VERV 0.49
  • TBLD 0.25
  • MACD
  • VERV -0.04
  • TBLD 0.01
  • Stochastic Oscillator
  • VERV 4.76
  • TBLD 68.55

About VERV Verve Therapeutics Inc.

Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.

About TBLD Thornburg Income Builder Opportunities Trust

Thornburg Income Builder Opportunities Trust is a diversified, closed-end management investment company. The Trust's investment objective is to provide current income. The Trust will seek to achieve its investment objective by investing, directly or indirectly, at least 80% of its Managed Assets.

Share on Social Networks: